'Mutational status' presentation slideshows

44th ASCO Annual Meeting May 30-June 3, 2008 McCormick Place, Chicago, Illinois

44th ASCO Annual Meeting May 30-June 3, 2008 McCormick Place, Chicago, Illinois. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment.

379 views • 26 slides

*Institute of Clinical Radiology and Nuclear Medicine

400 views • 20 slides

Age-Time Patterns of Radiation-Related Cancer Risk

265 views • 17 slides

Experimental Hematology, Institut Jules Bordet (ULB)

Comparison of Chronic Lymphocytic Leukemia patients expressing high or low level of ZAP70 mRNA: new prognostic factors, differences in microRNA expression and interaction with the microenvironment.

331 views • 16 slides

Authors: E. Van Cutsem, I. Lang, G. D'haens, V. Moiseyenko, J. Zaluski, G. Folprecht, S. Tejpar, O. Kisker, C. Stroh, P.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience.

256 views • 13 slides

Table S1. Mutational status of pancreatic cell lines used.

Table S1. Mutational status of pancreatic cell lines used.

87 views • 1 slides